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Abstract: Pharmacovigilance centres monitor the safety of drugs, based on adverse drug reactions (ADRs) reported by doctors,
pharmacists and pharmaceutical companies. However, the under-reporting of ADRs remains a major problem. Our aim was to
investigate preparedness of future doctors for their role in pharmacovigilance, by assessing their pharmacovigilance awareness,
skills and knowledge. The study was a nationwide e-survey among medical students (third to sixth year) of all eight medical
schools in the Netherlands. The survey consisted of questions regarding pharmacovigilance awareness, skills and knowledge.
Overall, 874 students provided informed consent and participated (response 12%). Almost all students (96%) intended to report
serious ADRs in their future practice. Almost half (44%) of the students did not know where to report an ADR, and 78% did
not know which items were necessary for a good-quality ADR report. While more than 78% of the students agreed that pharma-
covigilance is an important topic in their medical education, only 26% found that their current curriculum covered pharmacovigi-
lance adequately. Although ADR reporting is considered relevant and important among future doctors, many do not know where
and what to report. This is highly undesirable and should have consequences for pharmacotherapy teaching.
Pharmacovigilance centres have a vital function in safeguard-
ing patient safety and the appropriate use of medicines world-
wide, by monitoring the adverse drug reactions (ADRs) of
pharmaceutical products that have been given marketing
approval. Monitoring is essential to identify undetected,
uncommon and serious ADRs and to thereby improve medica-
tion safety and the understanding of drug risks [1–3]. The
spontaneous reporting of ADRs to pharmacovigilance centres
is a common and inexpensive method of ADR detection in
many countries [3], which makes centres dependent on the
quality and quantity of these spontaneous ADR reports.
Despite the recognized importance of post-marketing surveil-
lance, under-reporting remains a barrier for optimal ADR
monitoring [2,4,5]. Most ADRs are reported by health profes-
sionals [4,6,7], and in many countries, among which the
Netherlands, the reporting of serious or previously unrecog-
nized ADRs is mandatory. In some European countries, such
as Sweden, the Netherlands and Portugal, patients can also
report ADRs, and in the Netherlands, even medical and phar-
macy students can report ADRs to the Netherlands Pharma-
covigilance Centre Lareb [8–12].
The legal obligation to report ADRs requires health profes-
sionals to have the knowledge and skills to recognize and
adequately report these reactions. During their medical train-
ing, medical students are typically taught how to prescribe
rationally on the basis of the WHO Guide to Good Prescrib-
ing [13–15], and the last step of the six-step method covers
the follow-up of prescribing; however, it is not known
whether medical students are adequately prepared for their
role in monitoring and reporting ADRs. Previous studies
have shown that pharmacy students have insufficient knowl-
edge of pharmacovigilance and ADR reporting [1,16]. We
expected a similar insufficient preparedness among medical
students, and by identifying the nature of this insufficiency,
we would be able to improve future (medical) pharmacovigi-
lance education. Therefore, the primary objective of this
study was to investigate whether medical students are suffi-
ciently prepared for their role in pharmacovigilance. A sec-
ondary objective was to evaluate the intention/attitudes and
skills/knowledge of these students towards pharmacovigilance
and ADR reporting.
Author for correspondence: Tim Schutte, Department of Internal Medi-
cine, Pharmacotherapy Section, de Boelelaan 1118 1081 HZ, Amster-
dam, the Netherlands (e-mail: t.schutte@vumc.nl).
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Methods
Setting. This national, anonymous, cross-sectional study was carried
out on behalf of the working group ‘Pharmacotherapy Education
Research’ of the Dutch Society for Clinical Pharmacology &
Biopharmacy (NVKF&B), in collaboration with the Netherlands
Pharmacovigilance Centre Lareb (Lareb). The pharmacotherapy
education co-ordinators of the eight medical schools in the
Netherlands were invited to participate in this project. These co-
ordinators regularly attend meetings of the education subcommittee of
the NVKF&B to improve clinical pharmacology and pharmacotherapy
teaching [17]. The STROBE guidelines were followed where possible
[18].
Population. All students were invited by their medical school to
voluntarily complete an anonymous e-survey. We aimed to include
only third- to sixth-year medical students, as these students would
shortly start clinical practice, either as junior doctor or during
clerkships. We expected a response rate of 10–25%.
Instrument. The e-questionnaire started with an information letter and
informed consent statement and consisted of 10 questions (with some
questions consisting of multiple statements). If a question was
answered, it was not possible for respondents to return to earlier
answers (since some questions consisted of the answers on earlier
answered questions). There was no time limit for e-questionnaire
completion, but on the basis of a pilot study we estimated that it
would take 5–6 min. to complete the questionnaire. In this pilot study,
we also tested the face validity of the e-questionnaire in final-year
students who were not participating in the current study. Besides
participant characteristics (sex, study year, university), the survey
consisted of the following three themes.
Knowledge and skills. Knowledge and skills regarding
pharmacovigilance and ADR reporting were investigated using an
open-ended question and dichotomous questions. The open-ended
question was as follows: ‘If you think that a patient is having an
adverse drug reaction, what would you do?’ In four merged
dichotomous contingency questions (no/yes, specify your answer
(open-ended)), we investigated whether students knew where, how and
why to report ADRs and if they had reported an ADR before. For
example, if a participant answered ‘yes’ to the following question ‘I
know where I can report adverse drug reactions (in the Netherlands)’,
he/she would be asked to specify where they should make this report
(the Netherlands Pharmacovigilance centre Lareb). There were also
12 closed-ended dichotomous questions (yes/no). Of those, 9
questions had been used in an earlier survey for pharmacists and
pharmacy students and had been adapted for medical students
[6,16,19].
Intention / Attitudes. Intention and attitudes towards
pharmacovigilance/ADR reporting were evaluated using three
questions. The first question consisted of five statements on the
intention to report ADRs, three of which had been used earlier in the
survey of pharmacists and pharmacy students [6]. The other two
statements investigated the probability of the participant reporting an
ADR, dependent on the severity of the ADR and the participant’s
familiarity with the reaction. The second question probed opinions and
beliefs regarding ADR reporting and pharmacovigilance, using a
number of statements. Many of these statements are used during
pharmacovigilance teaching (see separate heading) and had been
adapted for medical students [1]. These statements were scored on a
5-point Likert scale (1: strongly disagree to 5: strongly agree). The
third question included eight statements on what students would
expect to be the likely outcome of reporting ADRs (7-point Likert
scale; 1: extremely unlikely to 7: extremely likely). The first seven
statements had been adapted from the study of Gavaza [16].
Student opinion of current pharmacovigilance teaching. The third and
last part of the survey covered students’ opinions of their current and
past education in pharmacovigilance, whether they considered this
education sufficient and appropriate for future clinical practice. Some
of the statements had been used previously and had been adapted for
medical students [1]. Answers were given on a 5-point Likert scale (1:
strongly disagree to 5: strongly agree). The participants were also
asked how they would prefer to be taught about pharmacovigilance
and ADRs.
Data analysis. All data were imported in SPSS Statistics 22 (IBM
Corp. Armonk, NY, USA). Descriptive statistics were used to report
frequencies and means/standard deviations (S.D.) of survey results.
Open questions were analysed using content analysis/thematic analysis
[20]. The mean aggregate intention score was calculated as the sum of
the original three intention statements [6]. The mean composite
knowledge score was calculated as the sum of the correct answers
divided by the number of answered questions (uncorrected for
guessing). Skills were analysed as two separate variable (i.e. knowing
where to report and knowing what to report). Reliability of the
composite intention was tested using Cronbach’s a. A one-way ANOVA
was used to compare the mean intention scores and composite
variable (intention, knowledge and skill scores) with baseline
characteristics (study year, medical school (anonymized)). If the
ANOVA tests revealed significant differences within a group, post hoc
tests were used to differentiate between subgroups. The Gabriel’s post
hoc test was used when sample sizes of these subgroups were slightly
different [21]. A significance level (p ≤ 0.05) was considered
statistically significant for all analyses.
Ethical considerations. This study did not fall under the scope of the
Dutch Medical Research Involving Human Subjects Act (WMO).
Participation was voluntary and anonymous, and all participants were
informed and gave informed consent based on an information letter.
Furthermore, the ethics review board of the Netherlands Association
for Medical Education (NVMO) reviewed and approved this research
(protocol) (ID: 440).
Results
In total, 874 students from the eight medical schools provided
informed consent and participated (baseline characteristics are
displayed in Table S1). Response rates varied between medical
schools and study year (mean 12%, range 7–24%). Of the 858
students who provided information about their study year, 354
were in their third year of medical school, 92 in their fourth
year, 106 in their fifth year and 298 in their sixth year. Most
(73%) of the participants were women and only 84 (10%) had
reported one or more ADRs before (range 1–5 reports); most
of these students (n = 57, 68%) were from ‘Medical school 10.
Almost all sixth-year medical students (94%) from ‘Medical
school 1’ had reported an ADR before, which was expected
given the mandatory ADR reporting instruction in that medical
school’s curriculum [9,12].
Knowledge and skills.
If the respondents detected an ADR in the future, most (70%)
would search for additional information (i.e. in the literature,
© 2016 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT
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take an extended history from their patient or suggest addi-
tional diagnostics) about that ADR. Almost half (47%) would
search for an alternative drug, 33% would withdraw the sus-
pect drug, and 21% would ask help/advice from their supervi-
sor or the hospital pharmacist. The action students took would
depend on the severity of the ADR (22%), and 16% indicated
they would report the ADR, either to some authority (i.e. in
general ‘I would report the ADR somewhere’ or specifically
‘Report the ADR to Lareb’). The number of sixth-year medi-
cal students who would report an ADR was only slightly
higher than that of students in other years (ANOVA p = 0.221),
being 18% (see how students would respond to an ADR in
Table S2).
Overall, 65% of the third-year and 22% of sixth-year stu-
dents did not know where they should report an ADR (one-
way ANOVA, p < 0.001, see fig. 1). However, more students
from ‘Medical school 1’ knew where they should report an
ADR compared with students from the other medical schools
(75% versus 31–53% in the other medical schools; one-way
ANOVA, Gabriel post hoc, p < 0.001 to p = 0.027). Of the stu-
dents who knew where they should report ADRs (n = 419),
93% mentioned Lareb and 8% mentioned that they would use
Internet to find out where they should report the ADR or
would report to another institution, such as the Dutch Drug
Formulary (Farmacotherapeutisch Kompas, 4%) (see
Table S3).
Almost none (90%) of the third-year medical students and
66% of the sixth-year students did not know which items were
necessary for a good ADR report (one-way ANOVA, p < 0.001,
see fig. 1). Students from ‘Medical school 1’ scored signifi-
cantly better (47.3%) than students attending the other medical
schools (range 81–88%, ANOVA, Gabriel post hoc, all
p < 0.001). The items the students mentioned as necessary for
a good ADR report are displayed in Table S4.
The mean score for the 12 dichotomous knowledge ques-
tions was 66% (not corrected for guessing; see table 1). Scores
differed significantly between study years but not between
medical schools (one-way ANOVA, p = 0.008 and p = 0.371,
respectively). In general, the sixth-year students scored mar-
ginally better (mean 68% S.D. = 14.2) than the third-year
medical students (mean 64% S.D. = 14.7) (one-way ANOVA,
Gabriel post hoc, p = 0.005). Students had the least knowl-
edge about which ADR should be reported to the Pharma-
covigilance Centre Lareb. Less than half of the students were
aware that patients and/or medical students could report ADRs
(even during their clerkships).
Intention and attitudes.
Almost all students intended to report future ADRs to Phar-
macovigilance Centre Lareb in different situations (see
table 2). The aggregate Intention score was reliable (Cron-
bach’s a = 0.918), and on average 18.27 (S.D. = 2.74), not
influenced by study year or medical school (one-way ANOVA,
p = 0.234 and p = 0.266, respectively). Students who had
reported an ADR earlier had a higher score (mean 18.86,
S.D. = 1.92) than the students who had not reported an ADR
earlier (mean 18.20 S.D. = 2.82) (one-way ANOVA, p = 0.040).
In the eight statements on what students expected to be the
likely outcome of reporting an ADR, they agreed to favour-
able outcomes (‘Contribute to the safe use of medicines’ and
‘Improve patient safety’). They did not anticipate that report-
ing would ‘Disrupt the normal workflow’ or be ‘Time-con-
suming’. The latter two were scored similarly by students who
had or had not previously reported an ADR (one-way ANOVA
p = 0.455 and p = 0.303, respectively).
Student opinion about current pharmacovigilance teaching.
Opinions and beliefs about ADR reporting and pharmacovigi-
lance were adapted to medical instead of pharmacy students
[1] and are reported in table 2. Overall, 79% of the students
agreed that pharmacovigilance should be an important compo-
nent of medical education, but only 26% agreed that their cur-
rent curriculum covered pharmacovigilance well. Only 48% of
the sixth-year medical students felt sufficiently prepared to
report ADRs in future practice. When asked how they would
prefer to learn about pharmacovigilance and ADRs, the major-
ity (76%) indicated they would prefer a practical assignment
(e.g. making an ADR report).
Discussion
Although ADR reporting is considered relevant and important
by future doctors, many medical students who will shortly
enter practice did not know what to do, and where and what
to report. Even though there is international recognition of the
importance of pharmacovigilance and ADR reporting, this has
not been accompanied by emphasis on ADR reporting in clini-
cal or teaching practice. This is highly undesirable and efforts
should be taken to improve pharmacovigilance skills and
knowledge among medical students.
We found that medical students did not know how to act if
they were to encounter an ADR in clinical practice – most
Fig. 1. Skills and knowledge of reporting adverse drug reactions and
pharmacovigilance among medical students in the Netherlands in dif-
ferent study years. Statistical significant differences are indicated with
an asterisk (*).
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would only look for more information or perform additional
tests. The emphasis on diagnostic testing instead of action and
(pharmaco)therapeutics is a notorious problem in medical
pharmacotherapy education [22,23]. Furthermore, only a small
minority of students spontaneously mentioned reporting an
ADR, similar to the estimated extent of under-reporting among
doctors [4]. Unexpectedly, a substantial proportion of sixth-
year medical students did not know to which authority they
should report ADRs. Although students’ skills and knowledge
about reporting seemed inadequate, they did recognize the
importance of ADR reporting, which we considered positive.
A previous literature review identified multiple factors as
underlying the low level of ADR reporting: indifference,
lethargy (including lack of motivation and time) and negative
expectations of the result of reporting were the most cited rea-
sons not to report [24]. As opposed to these findings, we
found students to have favourable intentions and attitudes
regarding ADR reporting. Almost all students intended to
report serious ADRs in the future. Moreover, with the same
questionnaire, medical students had higher scores than phar-
macists and pharmacy students [6,16]. Students who had
reported an ADR before expressed the intention to report seri-
ous ADRs in the future more often than students who had not
previously reported an ADR.
The results of this study, regarding the limited proficiency
in pharmacovigilance skills and knowledge among medical
students, can probably be generalized to medical schools in
other countries. The Netherlands has a long tradition in phar-
macovigilance and pharmacotherapy teaching and has been
an example for other (European) countries. Problem-based
pharmacotherapy teaching based on the WHO six-step
method has been implemented in the curricula of all medical
schools in the Netherlands [17,25]. The study had a number
of strong points, such as the inclusion of a large number of
students in the third to sixth year of medical training, the use
of validated questionnaires on ADR reporting knowledge and
attitudes, enabled us to compare the attitude and knowledge
of (future) health professionals, and the inclusion of open-
ended questionnaires provided information about how stu-
dents would currently respond to ADRs [1,6,16]. However, a
limitation of this study is self-selection bias, as students vol-
untarily and anonymously participated. The volunteers are
probably the ones most interested/concerned with the topic of
pharmacovigilance and would plausibly do better compared
to the less interested (non-responders). Our results might
therefore be an overestimation of the knowledge and attitude
to ADR reporting of medical students in general. The
response rate of 12% may be perceived as a limitation; how-
ever, still 874 students from all medical schools in the
Netherlands participated. Despite these shortcomings, the
study contributes to our knowledge of how students would
report ADRs and identified gaps in the their knowledge of
how, when and where to report such events. This knowledge
should be harnessed to improve the pharmacovigilance of
medical students and doctors.
The results for one of the medical schools were probably
influenced by a pilot project on ADR reporting run by Lareb.
Students from this medical school performed better regarding
where and what to report to the national pharmacovigilance
centre. Although results were promising, pharmacovigilance
should be further improved, by incorporating a (mandatory)
ADR reporting assignment in the medical curriculum. In col-
laboration with Lareb, an educational package consisting of
(digital) casuistry, a lecture and an ADR assignment has been
developed and is available to Dutch medical schools [9]. Vari-
ous efforts have been suggested to stimulate ADR Reporting
such as integrating a ‘ADR report link’ in an electronic medi-
cal record or using an app. Although these suggestions seem
promising, reporting ADRs still depends on the awareness and
skills of the (future) doctor. Another initiative that could fur-
ther improve pharmacovigilance awareness, knowledge and
skills is the student-led assessment of ADR reports as prac-
tised in the VUmc Learner centred student-run clinic project,
which is run in collaboration with the Netherlands Pharma-
covigilance Centre Lareb [26,27]. Further research is needed
to determine the feasibility and effects of these novel
Table 1.
Knowledge/skills regarding the reporting of adverse drug reactions of medical students in different study years, *correct answer, displayed % is %
of students with Correct Answer.
3rd year 4th year 5th year 6th year Total
1. All ADRs, irrespective of severity, must be reported (*No) 41.6% 35.4% 41.4% 56.9% 46.7%
2. Doctors should report serious ADEs even if uncertain that product caused the event (*Yes) 85.1% 87.7% 85.1% 83.9% 84.9%
3. Doctors should report serious ADEs even if do not have all details of event (*Yes) 80.1% 90.8% 75.9% 86.7% 83.0%
4. All serious ADRs are known before a drug is marketed (*No) 84.0% 90.8% 93.1% 91.4% 88.5%
5. Lareb does not disclose ADR reporter’s identity (*Yes) 86.5% 87.7% 83.9% 81.2% 84.3%
6. One can report ADEs anonymously to Lareb (*Yes) 81.9% 84.6% 81.6% 76.5% 80.1%
7. Adverse experiences with cosmetics and special nutritional products may
be reported to Lareb (*Yes)
38.1% 33.8% 32.2% 29.8% 33.9%
8. Adverse experiences with natural or homeopathic products may be reported to Lareb (*Yes) 52.3% 47.7% 57.5% 52.9% 52.8%
9. Adverse experiences with vaccines may be reported to Lareb (*Yes) 94.3% 100.0% 98.9% 95.7% 95.9%
10. One case reported by a doctor does not contribute much to knowledge on drug risks (*No) 65.8% 70.8% 73.6% 72.9% 69.9%
11. I have adequate knowledge of ADE reporting (*Yes) 16.0% 13.8% 40.2% 40.8% 28.1%
12. Patients can report ADRs independent from a healthcare professional (*Yes) 46.3% 49.2% 48.3% 52.5% 49.1%
Total 12 knowledge questions 64.3% 66.0% 67.6% 68.4% 66.4%
© 2016 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT
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Table 2.











Could you indicate how likely it is you will report an ADR to Lareb in the following situations:
(General) I plan to
report ADRs that
I will encounter
716 4.95 (1.23) 0.6% (4) 3.1% (22) 8.8% (63) 18.6% (133) 35.6% (255) 24.6% (176) 8.8% (63)




716 5.59 (1.11) 0.6% (4) 1.1% (8) 3.5% (25) 6.8% (49) 29.7% (213) 38.4% (275) 19.8% (142)
I intend to report
serious ADRs that
I encounter
716 6.17 (0.95) 0.7% (5) 0.4% (3) 0.4% (3) 2.2% (16) 13.5% (97) 41.1% (294) 41.6% (298)
I will try to report
serious ADRs that
I encounter
716 6.10 (1.00) 0.8% (6) 0.4% (3) 1.0% (7) 3.1% (22) 13.7% (98) 42.3% (303) 38.7% (277)
I plan to report
serious ADRs that
I encounter




How likely do you think the following outcomes will be if you report a serious ADR:
Educates others
about drug risks
674 5.83 (0.99) 0.6% (4) 0.7% (5) 1.3% (9) 3.6% (24) 23.7% (160) 46.1% (311) 23.9% (161)
Personally beneficial 674 3.81 (1.55) 7.0% (47) 16.3% (110) 17.5% (118) 27.0% (182) 16.2% (109) 12.6% (85) 3.4% (23)
Improves patient
safety
674 6.06 (0.91) 0.4% (3) 0.6% (4) 0.7% (5) 1.6% (11) 16.8% (113) 46.7% (315) 33.1% (223)
Increases risk of
malpractice
674 2.84 (1.32) 16.3% (110) 27.4% (185) 26.7% (180) 20.6% (139) 4.6% (31) 3.3% (22) 1.0% (7)
Breaks trust with
patients
674 2.32 (1.12) 23.4% (158) 38.7% (261) 27.9% (188) 5.8% (39) 1.8% (12) 1.6% (11) 0.7% (5)
Disrupts the normal
workflow
674 4.09 (1.52) 4.9% (33) 11.7% (79) 17.7% (119) 22.8% (154) 26.7% (180) 10.1% (68) 6.1% (41)
Time-consuming
to report




674 6.06 (0.96) 0.7% (5) 0.6% (4) 0.3% (2) 2.1% (14) 18.0% (121) 43.5% (293) 34.9% (235)
N Mean (S.D.)
Completely
disagree Disagree Neutral Agree
Completely
agree
Opinion regarding (current) education in pharmacovigilance
Pharmacovigilance should be included as
a core topic in medical education
724 3.87 (0.70) 0.4% (3) 4.3% (31) 16.7% (121) 65.3% (473) 13.3% (96)
Pharmacovigilance is well covered (up to
now) in my medical school curriculum
724 2.75 (0.99) 8.8% (64) 35.6% (258) 29.3% (212) 24.0% (174) 2.2% (16)
I don’t know how I could report an ADR
to the relevant authorities
724 2.86 (1.30) 17.1% (124) 29.4% (213) 14.1% (102) 28.6% (207) 10.8% (78)
Opinion regarding current and future role in pharmacovigilance
Medical students can report ADRs
during their clerkships
724 3.18 (1.02) 4.8% (35) 20.6% (149) 36.5% (264) 28.2% (204) 9.9% (72)
Reporting known ADRs makes no
significant contribution to the reporting
system
724 2.24 (0.98) 20.7% (150) 50.7% (367) 15.1% (109) 11.3% (82) 2.2% (16)
With my present knowledge, I am very
well prepared to report any ADRs in
my future practice
724 2.77 (1.02) 7.0% (51) 41.9% (303) 21.5% (156) 26.4% (191) 3.2% (23)
I believe that doctors are one of the most
important healthcare professionals to
report ADRs
724 3.98 (0.75) 1.0% (7) 3.7% (27) 12.0% (87) 63.3% (458) 20.0% (145)
I believe that pharmacists are one of the
most important healthcare professionals
to report ADRs
724 3.73 (0.92) 1.0% (7) 12.0% (87) 17.7% (128) 51.8% (375) 17.5% (127)
I believe serious and unexpected reactions
that are not fatal or life-threatening during
clinical trials should not be reported
724 1.43 (0.65) 63.5% (460) 31.8% (230) 3.3% (24) 0.8% (6) 0.6% (4)
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educational approaches to pharmacotherapy education for
undergraduate medical students.
In this study, students expressed a desire to be taught more
about pharmacovigilance during their medical education and
would prefer to learn in real-life practice. We urge (inter)na-
tional pharmacovigilance centres to collaborate with clinical
pharmacology teachers to develop educational interventions
that can be incorporated in the formal medical curriculum.
One such easy-to-implement intervention is an ADR reporting
assignment [12]. Further research is needed to design and
evaluate new educational interventions to stimulate early clini-
cal pharmacovigilance experiences for undergraduate medical
students and to assess the effect of these new interventions. In
this way, when junior doctors start to work in clinical practice,
they will know what to do and where/what to report when
they encounter an ADR.
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